β‘ ππππππ: $ImmunityBio(IBRX.US) ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain BCG
π πππ² ππ’π π‘π₯π’π π‘ππ¬:β€ ImmunityBio signs exclusive U.S. agreement with πππ©ππ§ πππ ππππ¨π«πππ¨π«π².β€ Deal targets long-standing π.π. πππ π¬π‘π¨π«πππ π in bladder cancer treatment.β€ Agreement covers development and commercialization of ππ¨π€π²π¨-πππ πππ.β€ Phase III SWOG S1602 study showed π§π¨π§-π’π§πππ«π’π¨π«π’ππ² versus TICE BCG.β€ Tokyo strain achieved ππ% π-π²πππ« high-grade recurrence-free survival.β€ Product remains π’π§π―ππ¬ππ’π πππ’π¨π§ππ₯ and unapproved by the FDA in the U.S.β€ ImmunityBio plans FDA engagement and πππ submission using S1602 data.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments